International Stem Cell Corporation (OTCBB:ISCO) announced today that it
has entered into an agreement with ATCC (American Type Culture
Collection, Manassas, Va.) to manufacture living primary cells and cell
culture products for worldwide distribution by ATCC into the biological
research market.
"We are proud of our relationship with ATCC.
They are well known around the world as a leader in supplying
biomaterials for critical research being conducted in the field of life
sciences," according to Jeffrey Janus,
President of ISCO. "Relationships with quality
organizations such as ATCC are critical to ISCO's
future success. This is yet another important step toward ISCO's
becoming the industry leader in providing cells and cell products for
therapy. We advance our therapeutic goals by generating revenue,
scientific knowledge and infrastructure through research, product
manufacture and sales."
International Stem Cell Corporation is the first company to perfect a
method of creating human stem cells from unfertilized eggs. These cells,
called "parthenogenetic"
stem cells alleviate two critical problems inherent in cell
transplantation today — immune rejection and
the ethical issues associated with the use of fertilized human embryos —
yet they retain the ability to differentiate into all tissue types.
"These products and the expertise of ISCO
broaden the ATCC offering and complement our strong position in cell
biology," said Michael Gove, ATCC VP for
Marketing and Sales. "Offering primary cells
and culture products will enhance our position as the world's
leading biological resource center and provide our customers more
high-quality reagents for their research."
ATCC, a global nonprofit, supports biological research by acquiring,
authenticating, developing, preserving and distributing the world's
most comprehensive source of cell and microbial reference cultures and
reagents. ATCC functions as a biological repository, a research
organization and a service provider for use by researchers in academic
and industry laboratories.
ISCO, through its wholly owned subsidiary, Lifeline Cell Technology
(Walkersville, MD) develops and manufactures optimized human cell
culture products for research use. These products consist of frozen
cells and cell culture media and reagents and include stem cell products.
About ATCC:
ATCC is the world's largest biological
resource center and the most comprehensive source of reference cultures
and reagents used by researchers in academic and industry laboratories.
Since 1925, ATCC, also known as American Type Culture Collection, has
set the standard for authentication and distribution of biological
reference materials for life science research in the public and private
sector. www.atcc.org.
About International Stem Cell Corporation (ISCO.OB):
International Stem Cell Corporation (ISCO) is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists also have created the first Parthenogenetic homozygous
stem cell line (phSC-Hhom-4) that can be a source of therapeutic
cells that will not be immune rejected after transplantation into
millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by
eliminating the need to use or destroy fertilized embryos. ISCO also
produces and markets specialized cells and growth media worldwide for
therapeutic research through its subsidiary Lifeline Cell Technology.
For more information, visit the ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements.
KEYWORDS: Stem Cells, Biotechnology, Parthenogenesis |